1 |
Tan PS, Haaland B, Montero AJ, et al (2014). Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol, 8, 29-36.
|
2 |
Zhou ZR, Liu SX, Zhang TS, et al (2014). Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 1313-20.
DOI
|
3 |
Beer TM, Armstrong AJ, Rathkopf DE, et al (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med, 371, 424-33.
DOI
|
4 |
de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005.
DOI
|
5 |
de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-54.
DOI
|
6 |
Efstathiou E, Titus MA, Wen S et al (2014) Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol, 32, 5000.
|
7 |
Iranikhah M, Stricker S, Freeman MK (2014). Future of bisphosphonates and denosumab for men with advanced prostate cancer. Cancer Manag Res, 6, 217-24.
|
8 |
Lee JL, Park SH, Koh SJ, et al (2014). Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. Cancer Chemother Pharmacol. [Epub ahead of print].
|
9 |
Scher HI, Fizazi K, Saad F, et al (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 1187-97.
DOI
|